Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (111-120 of 210) with videos related to

Pageof 21
Sort By:
Breast Cancer Research and Treatment|August 11, 2020
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathwayArielle L Heeke, Joanne Xiu, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri, Jennifer A Low, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancerAntoinette R Tan, Xiaowei Yang, Arlene Berman, et al.
Clinical and Translational Science|January 22, 2020
Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory SettingsD Max Smith, Beth N Peshkin, T Blaise Springfield, et al.
Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
NPJ Breast Cancer|May 14, 2026
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41Ilana Schlam, Gong Tang, Khalid AbdulJabbar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsAntoinette R Tan, Donna Headlee, Richard Messmann, et al.
Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low, Suparna B Wedam, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox, Jennifer Low, James Lee, et al.
Pageof 21

Showing results (111-120 of 210) with videos related to

Sort By:
Pageof 21
Breast Cancer Research and Treatment|August 11, 2020
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathwayArielle L Heeke, Joanne Xiu, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri, Jennifer A Low, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancerAntoinette R Tan, Xiaowei Yang, Arlene Berman, et al.
Clinical and Translational Science|January 22, 2020
Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory SettingsD Max Smith, Beth N Peshkin, T Blaise Springfield, et al.
Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
NPJ Breast Cancer|May 14, 2026
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41Ilana Schlam, Gong Tang, Khalid AbdulJabbar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsAntoinette R Tan, Donna Headlee, Richard Messmann, et al.
Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low, Suparna B Wedam, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxelMichael C Cox, Jennifer Low, James Lee, et al.
Pageof 21